Key result
Anti-fibrin antibody Nb106 reduces thrombin capacity ~55% by displacing fibrin-bound thrombin.
Case-Control (n=85)
Yes
Answers are grounded in this paper and cite their sources.
Explores how fibrin-bound thrombin affects clot structure and thrombogenicity in fibrinogen disorders, suggesting new therapeutic options.
In thrombosis and haemostasis, coagulation and platelet activation pathways culminate to form solid fibrin clots, which can become vaso-occlusive or prevent excessive bleeding. We report a novel mechanism describing how developing fibrin clots prolong and modulate the reactivity of thrombin, an enzyme propagating platelet and coagulation activation and forming fibrin from fibrinogen. Using immunological and genetic approaches, we delineate how thrombin bound to the A and Baachains of fibrin E-domains regulates lateral fibrin fibre extension. Our data reveal that fibrin-bound thrombin remains active and is temporarily protected against inactivation by antithrombin-III. Immunological displacement of thrombin from fibrin profoundly lowered its capacity, whereas a peptide mimicking the AA-chain binding-site increased its reactivity. In a cohort of patients with congenital dysfibrinogenemia, carrying FGA, FGB or FGG mutations associated with bleeding or thrombosis phenotypes, we noticed a high thrombin capacity and suppressed thrombinantithrombin-III complex formation, pointing to a prolonged active thrombin lifetime, likely due to abnormal formation of thrombin-containing fibrin. In conclusion, the combination of an impaired clotting and increased thrombogenicity may explain the paradoxical bleeding and thrombotic complications observed in such patients. Development of fibrin-directed agents may offer new therapeutic opportunities to normalize hemostasis or prevent thrombosis.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) conducted a case-control in Congenital dysfibrinogenemia (n=85). Anti-fibrin single chain antibody Nb106 (in vitro) / Congenital dysfibrinogenemia mutations (FGA, FGB, FGG) vs. Healthy controls / Vehicle control was evaluated on Reduction in tissue factor-triggered thrombin capacity (endogenous thrombin potential) by Nb106 (150 μg/mL) in healthy donor plasmas (p=<0.05). Anti-fibrin single-chain antibody Nb106 displaced fibrin-bound thrombin, reducing thrombin capacity by 55±12% and shortening average thrombin lifetime by 2.2-fold in plasma.
Synapse has enriched 10 related papers. Consider them for comparative context: